- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits

# Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits

Cancer-specific biomarkers are emerging faster than CTC assays can be built to measure them — this AACR 2020 poster adds up to 2 user-selected antibodies to a validated three-channel CTC detection assay with RarePlex Developer Kits, then reads them on model CTCs and on prostate and breast cancer patient samples.

Presented by RareCyte / University of Washington.

Read or download to see:

- Developer Kits add two open channels to a validated three-channel CTC assay. The RarePlex CTC Panel Kit identifies CTCs with a nuclear dye, anti-CD45 to exclude white blood cells, and cocktailed cytokeratin and EpCAM antibodies, leaving Developer Kits to carry up to 2 user-selected markers — tested here across HER2, ER, PR, Vimentin, SYP, EGFR, Ki67, AR, ARv7 and PSMA, each with the expected localization on model CTC control cells under default antigen retrieval and fixation.

- Marker-positive and marker-negative cell lines separated cleanly on median cell intensity. In spiked model CTCs, ARv7 read a median MFI of 403.0 on 22Rv1 against 36.8 on the negative BT474 line, and PSMA read 161.0 on LNCaP against 12.2 on MCF7; fluorescence intensity cut-offs segregating the negative and positive lines were then defined statistically for each biomarker.

- A breast cancer patient's two tumor phenotypes both appeared among the CTCs. That patient carried both ER+/HER2- and ER+/HER2+ tumors, and the same heterogeneity showed in the CTCs: 13 scored ER+/HER2+ and 3 ER+/HER2-, alongside 3 ER-/HER2+ and 2 ER-/HER2-; in a prostate cancer patient, 26 CTCs scored AR+/ARv7- and 4 AR+/ARv7+, against 13 AR-/ARv7- and 0 AR-/ARv7+.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024
### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood
[Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024
### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024
### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) CyteFinder The Journal of Liquid Biopsy 2023
### Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) CyteFinder 2023
### Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) CyteFinder 2020
### Validation of a dual-marker ARv7/SYP assay for CTC characterization
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) CyteFinder 2020
### Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) [Video](https://www.youtube.com/watch?v=A0dhlNEaohs) CyteFinder 2020
### RarePlex Assays: Design and Analytical Validation
[Watch Video](https://www.youtube.com/watch?v=A0dhlNEaohs) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) CyteFinder 2020
### Validation of an assay to detect programmed death-ligand 1 (PD-L1) expression on circulating tumor cells
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) CyteFinder 2019
### Custom biomarker investigation of circulating tumor cells using RarePlex® Developer Kits
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf) CyteFinder 2018
### Novel multi-parameter assays for investigational phenotyping of circulating tumor cells
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf)